CagriSema vs SHLP2
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
CagriSema
CagriSema is a fixed-ratio combination of cagrilintide (a long-acting amylin analog) and semaglutide, developed by Novo Nordisk. By combining two distinct appetite-regulating peptide hormones, CagriSema aims to achieve greater weight loss than semaglutide alone. Phase 3 data showed 22.7% body weight reduction, and an FDA response is expected in 2026.
Full details →SHLP2
SHLP2 (Small Humanin-Like Peptide 2) is a mitochondrial-derived peptide similar to humanin. It has shown insulin-sensitizing and cytoprotective effects in research, with potential metabolic benefits.
Full details →Side-by-Side Comparison
| Aspect | CagriSema | SHLP2 |
|---|---|---|
| Mechanism | CagriSema combines two complementary peptide mechanisms: (1) Semaglutide — GLP-1 receptor agonist providing glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and hypothalamic appetite suppression. (2) Cagrilintide — a long-acting analog of amylin, a peptide hormone co-secreted with insulin from pancreatic beta cells. Amylin activates amylin receptors (calcitonin receptor + RAMP complexes) in the area postrema and hypothalamus, providing additional appetite suppression via a distinct neuronal pathway from GLP-1. The combination produces additive weight loss by engaging two independent satiety signaling systems. | Enhances insulin sensitivity and glucose uptake. Provides cytoprotective effects similar to humanin. May act through similar but distinct receptor pathways. |
| Typical Dosage | Phase 3 trial doses: cagrilintide 2.4 mg + semaglutide 2.4 mg weekly (fixed combination in a single injection). Dose escalation: start at cagrilintide 0.15 mg / semaglutide 0.25 mg weekly and escalate over 16 weeks to the maintenance dose. Administered as a single injection combining both peptides. | Research compound with doses in the microgram to low milligram range studied in animal models. Human dosing not established. |
| Administration | Single subcutaneous injection once weekly, combining both peptides. Pre-filled pen device. Not yet commercially available. FDA response expected 2026. | Subcutaneous or intraperitoneal injection in research settings. Various SHLP analogs (1-6) have different properties. |
| Side Effects | Phase 3 data: nausea, vomiting, diarrhea, constipation (similar profile to semaglutide alone, but some reports suggest modestly higher GI rates). Decreased appetite. Injection site reactions. | Limited data. Animal studies suggest good tolerability. May affect glucose metabolism. |
| Best For |
Key Differences
Unique to CagriSema:
Unique to SHLP2:
Detailed Analysis
Commonalities
CagriSema and SHLP2 are used for different purposes and have limited overlap in their applications.
Which Should You Choose?
Choose CagriSema for Weight Loss, Diabetes Management. Choose SHLP2 for Fat Loss, Anti-Aging & Longevity.
Ready to Learn More?
Looking for trusted sources?